

INTERNATIONAL PROJECT		Project under Management <input type="text"/>
Summary Form: DST-TDB & CDTI Call 2024	Agreement Reached <input type="text"/>	
Input date:	Country of origin: India Country of Interest: Spain	

✓ <u>Information of the company requesting the partner search service</u>							
Name of the company		Aurigene Oncology Limited					
Contact Person (full name, position)		Priyadarshini Chatterjee					
Address		39-40 Hosur Road KIADB Industrial Area, Joggers Ln, Phase 2, Electronic City					
Zip Code and City		Bangalore, Karnataka, India - 560100					
Telephone		+91-7483003547					
Email		priyadarshini_c@aurigene.com					
Web Page		www.aurigene.com					
Last exercise Revenues M\$	30931 Lakhs INR 35.5 M USD (USD to INR conversion taken as 87)	Number of employees	480	Year of Constitution	2002	Social Capital M\$	Not Applicable
<p>Founded in 2002, Aurigene is a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer. The company has deep expertise in oncology focused novel therapeutics for the benefit of cancer patients. Since inception, we have discovered 20 novel entities for clinical development. We have out-licensed several of these to pharmaceutical and biotech companies, while advancing a few on our own. We have built comprehensive drug discovery and development capabilities, nurtured a growing team of passionate scientists, and collaborated with partners across the world. Specifically with respect to Cell and Gene Therapy (CGT) products, we have completed a Phase 1 clinical trial of Ribre-Cel (an anti BCMA CAR-T) in multiple myeloma patients which demonstrated acceptable safety and 100% response rate. The Phase 2 study of Ribre-Cel has now started. We have also submitted an IND to CDSCO office in India for a Phase 1 / 2 trial of an anti CD19 CAR-T. We believe that biological therapies like bi-specifics, tri-specifics and CGT products will be the future of anti-cancer treatment.</p>							

✓ <u>Information of the Technology Collaboration Project</u>
Project idea, description of project objectives and type of collaboration wanted Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. The vast majority of clinical applications involves an ex vivo modality whereby lentiviral vectors are used to transduce autologous somatic cells, obtained from patients and re-

delivered to patients after transduction. Last year has seen unprecedented progress in development of Gene therapy approaches for CAR-T cells. In Aug'24, FDA has cleared an IND application for Umoja Biopharma's UB-VV111, a gene therapy product intended to create CD19-directed CAR T-cells within the body, allowing the company to go forward with a phase 1 dose escalation trial in hematologic malignancies. Although 90% of all cancers manifest as solid tumors, conventional CAR T-cell immunotherapies have been found to be effective in only hematologic cancers, leaving limited treatment options for patients with solid tumor cancers. Due to the tumor's hostile microenvironment, immune cells produced by current CAR T-cell treatments are disabled by the tumor's own protective mechanisms. Furthermore, the diversity of cells in solid cancers enables some to escape immune targeting, resulting in metastasis to other parts of the body. Here, we propose to develop a lentiviral vector platform, targeted to specific cell populations within the tumor microenvironment thereby delivering genes for highly potent pro-inflammatory mediator. This we believe would help reverse the tumor microenvironment's immunologically "cold" state and help in tumor regression.

With regards to the above Project idea, we are greatly interested in collaborating with Spanish Biotechs or Pharma companies with interest in development of lentiviral modes of Gene delivery, more broadly companies that are interested in development of novel Cell and Gene Therapy products.

Estimated budget of the project :

Estimated Foreseen Budget M€	0.67 M€	New Partner contribution M€	25% (0.1675 M€)
Public Funds %	50% (0.335 M€, combined from Govt of India and Govt of Spain)	Funding % (by Aurigene)	25%(0.1675 M€)

✓ **Profile of the partner wanted: activities to do by the new partner**

Summary of the activities to be developed by the partner. Please be as specific as possible.

Criteria required from the partner (expertise or know-how in a specific area, technical equipment needed, etc.)

Technology Partners experienced Lentiviral Vector delivery systems and/or Cell and Gene Therapy.

We can also help you to contact partners that you have already identified but you have not contacted yet. If this is the case, please provide us with the contact details of the company you would like to contact.

None

✓ <u>Potential Partner Information</u>	
Name of the firm	
Contact Person (name, position)	
Address	
Zip Code and City	
Telephone	
Email	
Web Page	

✓ <u>Potential Partner Information</u>	
Name of the firm	
Contact Person (name, position)	
Address	
Zip Code and City	
Telephone	
Email	
Web Page	